PharmaMar’s core business is oncology and it fully owns other companies that cover different aspects of healthcare.
As a global company, GENOMICA is focused on developing in vitro molecular diagnostics that are efficient tools for detection of infectious diseases and cancer mutations in clinical practice anticancer therapies.
As an emerging business in the field of RNAi-derived drugs, Sylentis is developing a novel RNAi platform to address unmet medical needs in the area of ocular diseases.
The Senior Management of PharmaMar is entrusted with the task of defining and implementing the Company´s strategy.
Shareholders and Investors
Financial Information of the Company, stock information, official notices to the CNMV (Spanish Securities & Exchange Commission), product portfolio and other information.
If you need information about the company, our clinical trials, corporate images or multimedia, visit our newsroom